-- Wedbush週三發布的研究報告指出，AMC娛樂（AMC）憑藉其在北美的高端銀幕佈局以及在英國和歐盟的擴張計劃，預計在2026年獲得更大的市場份額。 Wedbush表示，他們仍然看好AMC娛樂公司，因為該公司預計在未來幾季受益於更穩定的影片發行，並且繼續優先償還債務。 該券商在指出AMC娛樂公司第一季的業績時表示，該公司持續提升每位觀眾的觀影收入，過去三個季度其國內每位觀眾的觀影收入約為24美元，國際觀眾約為18美元，比疫情前水準高出約30%。 Wedbush表示：“我們預計，隨著觀影人數和每位觀眾的觀影收入逐步恢復正常，AMC的息稅折舊攤銷前利潤率將在未來2-5年內升至13-16%。” Wedbush維持對AMC娛樂的「跑贏大盤」評級，目標價為3美元。
Price: $1.63, Change: $+0.04, Percent Change: +2.52%
Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%
Price: $15.79, Change: $-4.34, Percent Change: -21.55%
Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%